The U.S. Food and Drug Administration has approved the first new treatment in three decades for a common rapid heart rhythm condition, offering patients a self-administered option to manage sudden episodes at home. The drug, CARDAMYST (etripamil), is a nasal spray approved for adults with paroxysmal supraventricular tachycardia (PSVT), which causes abrupt heart rate spikes that often lead to emergency room visits.
CARDAMYST is a calcium channel blocker designed as a rapid-response therapy that patients can use without immediate medical supervision. It is intended to convert acute symptomatic PSVT episodes back to a normal sinus rhythm. This approval marks a significant shift in managing a condition where the standard of care has for decades involved invasive procedures or drugs administered in a clinical setting. The company reports early commercial launch engagement with providers and patients is meeting or exceeding expectations.
For patients, this portable treatment promises a greater sense of control and active management of their condition. The availability of a self-administered option could reduce the anxiety associated with PSVT episodes and potentially decrease the need for urgent medical interventions. The product is well-studied with a robust clinical trial program that includes completed Phase 3 trials for PSVT in adults.
Looking ahead, research is expanding into other potential uses for etripamil. The drug is currently in Phase 2 development for treating PSVT in pediatric patients and in Phase 3 development for controlling acute atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. The approval and successful launch of CARDAMYST represent a hopeful new chapter for patients with episodic heart rhythm disorders, moving treatment from the clinic directly into their hands.